Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05852470 · ClinicalTrials.gov registry record · NA
Evaluation of Clareon Vivity/Vivity Toric
A NA study, sponsored by Alcon Research.
- Completed
- Registry status
- NA
- Development phase
- 155
- Enrollment target
NCT05852470: Completed NA study, sponsored by Alcon Research.
NCT05852470 is a NA study that has completed, run by Alcon Research. The registered enrollment target is 155 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05852470, a NA study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
Study Summary
This study seeks to generate clinical data from subjects previously implanted with the Clareon Vivity/Vivity Toric Intraocular Lenses (IOLs) or Clareon Monofocal/Clareon Toric IOLs. This study will assess key performance endpoints to support clinical benefits statements with model-specific data.
Primary Outcome
Visual acuity (VA) was assessed with best refractive correction in place under photopic (well-lit) conditions at a distance of 4 meters (m) using a visual acuity chart. VA was measured in logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity, with a lower logMAR value indicating better visual acuity. This was a subject-based assessment. Both eyes were assessed together. This is a co-primary endpoint.
Interventions
- DEVICE Clareon Vivity/Vivity Toric Extended Vision IOL
- DEVICE Clareon Monofocal/Clareon Toric IOL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2023-10-27 |
| Phase | NA |
What the finished NCT05852470 record still lists
NCT05852470 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Clareon Vivity/Vivity Toric Extended Vision IOL is the first listed.
NCT05852470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05852470 about?
NCT05852470 is a clinical study titled "Evaluation of Clareon Vivity/Vivity Toric". This study seeks to generate clinical data from subjects previously implanted with the Clareon Vivity/Vivity Toric Intraocular Lenses (IOLs) or Clareon Monofocal/Clareon Toric IOLs. This study will assess key performance endpoints to support clinical benefits statements with model-specific data.
What is the current status of trial NCT05852470?
This trial is currently completed. It is a NA study. The enrollment target is 155 participants. The study started on 2023-05-23. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT05852470?
The interventions under investigation include: Clareon Vivity/Vivity Toric Extended Vision IOL (DEVICE), Clareon Monofocal/Clareon Toric IOL (DEVICE).
Who is sponsoring clinical trial NCT05852470?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05852470's enrollment target sits among peer trials
155 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI